North America Meglitinide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The North America meglitinide market is segmented by geography (the United States, Canada, and the rest of North America). The report offers the value (in USD) and volume (in units) for the above segments.

North America Meglitinide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

North America Meglitinide Market Size

View Global Report
North America Meglitinide Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 1.50 %

Major Players

North America Meglitinide Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of North America Meglitinide Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

North America Meglitinide Market Analysis

The North America Meglitinide Market is expected to register a CAGR of 1.5% during the forecast period.

In North America, the United States is having the highest number of COVID cases with 82 million in April 2022, the country also registered the highest death rate. In the North American region diabetes patients are more concerned about stocking up the monitoring and managing devices due to this the market increased during these years. The North American region had witnessed an astounding increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates.

Meglitinides are a type of non-sulfonylurea insulin secretagogues with a fast onset and short duration of action. They stimulate glucose-sensitive first-phase insulin release, lowering the risk of hypoglycemia. Meglitinides cause the body to release more insulin in people with type 2 diabetes, who have chronically high blood sugar levels.

The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.

This is driving the demand for Meglitinides in North America, thereby driving the market in focus during the forecast period.

North America Meglitinide Industry Overview

The North American meglitinides market is fragmented, with manufacturers like Novo Nordisk, Glenmark, and Novartis having a global market presence, and the market is highly competitive due to generic drug manufacturers' presence.

North America Meglitinide Market Leaders

  1. Novo Nordisk

  2. Glenmark

  3. Novartis

  4. KISSEI

  5. Biocon

  6. *Disclaimer: Major Players sorted in no particular order
North America Meglitinide Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

North America Meglitinide Market News

  • March 2023: A randomized, open-label, controlled, parallel-group, multicenter trial is being conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
  • January 2023: OXJournal reviewed the effects of meglitinides as a class of oral medications for treating type-2 diabetes, especially in young adults.

North America Meglitinide Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Segmentation

  • 5.1 Drug
    • 5.1.1 Meglitinides
  • 5.2 Geography
    • 5.2.1 United States
    • 5.2.2 Canada
    • 5.2.3 Rest of North America

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Novartis
    • 7.1.3 Glenmark
    • 7.1.4 Boehringer Ingelheim
    • 7.1.5 Biocon
    • 7.1.6 Kissei Pharmaceuticals
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
* We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents. **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

North America Meglitinide Industry Segmentation

Oral medicines called meglitinides are used to treat type-2 diabetes. They function by causing insulin to be produced. Prandin (repaglinide) and Starlix (nateglinide) are two medications in this family. The North American meglitinide market is segmented by geography (United States, Canada, and the Rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. The report provides a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.

Drug Meglitinides
Geography United States
Canada
Rest of North America
Need A Different Region or Segment?
Customize Now

North America Meglitinide Market Research FAQs

What is the current North America Meglitinide Market size?

The North America Meglitinide Market is projected to register a CAGR of 1.5% during the forecast period (2025-2030)

Who are the key players in North America Meglitinide Market?

Novo Nordisk, Glenmark, Novartis, KISSEI and Biocon are the major companies operating in the North America Meglitinide Market.

What years does this North America Meglitinide Market cover?

The report covers the North America Meglitinide Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the North America Meglitinide Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

North America Meglitinide Industry Report

Statistics for the 2025 North America Meglitinide market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Meglitinide analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.